Material Sciences Corp. (Nasdaq:MASC) a leading provider of material-based solutions for acoustical and coated applications, announced it will report results for its fiscal 2011 third quarter on Friday, January 14, and follow this with a conference call at 9:00 a.m. Central Time.
Clifford D. Nastas, chief executive officer, and James D. Pawlak, vice president, chief financial officer, corporate controller and corporate secretary, will discuss the company's financial performance and answer questions from the financial community.
Material Sciences Corporation, together with its subsidiaries, engages in the design, manufacture, and marketing of material-based solutions for acoustical and coated applications in the United States and internationally.
What is Enzo Clinical Labs?
Enzo Clinical Labs is a full service clinical reference laboratory.
They are one of the leading regional labs in the country, as we combine the extensive testing capabilities of a large laboratory with the convenience and personalized service of a local one.
Enzo was one of the area’s first laboratories to be awarded the prestigious College of American Pathologist (CAP) accreditation. This award indicates that Enzo has passed an extremely rigorous series of inspections far more sophisticated than those mandated by licensing authorities
Their technical staff is led by board-certified pathologists and technical managers who combine many years of clinical experience with the desire to produce the highest quality laboratory results. Enzo’s Quality Control program (QCP) was developed by clinical experts, and is among the most comprehensive in the industry.
Their facilities are equipped with a state-of-the-art computer and communications system to allow rapid transmission of results to client physicians. In addition, Enzo maintains a broad menu of routine and esoteric clinical assays utilizing the latest in laboratory technology.
Q.When was Enzo Biochem founded?
A.The Company began operations in August of 1976.
Q.Who is the Company’s transfer agent?
A.The Company’s transfer agent is American Stock Transfer & Trust Company. Their telephone number is (718) 921-8380. If you have lost or have any questions in regards to your certificates, please call the transfer agent.
Q.When is the Company’s fiscal year?
A.The Company’s fiscal year ends on July 31st. The annual form 10-K is due to filed within 90 days of the fiscal year end. The fiscal quarters end on October 31st, January 31st and April 30th. The forms 10Q are to be filed 45 days after the respective quarter ending dates.
About Enzo Biochem
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field.
Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, Eastern Pennsylvania and New Jersey.
Rudolph Technologies Inc. (Nasdaq:RTEC) a leading provider of process characterization equipment and software for the semiconductor manufacturing industry, announced that it has received multiple orders for its NSXÂ® Inspection System from a major European semiconductor manufacturer.
The equipment will be used in back-end manufacturing for high-throughput inspection of automotive semiconductor devices at key points in the process. Shipments will commence in 1Q11 and continue through 2Q11.
Rudolph Technologies, Inc. engages in the design, development, manufacture, and support of process control metrology, defect inspection, and data analysis systems used by semiconductor device manufacturers worldwide.
ORFG, Orofino Gold Corp., ORFG.PK
Although primarily used as a store of value, gold has many modern industrial uses including dentistry and electronics. Gold has traditionally found use because of its good resistance to oxidative corrosion and excellent quality as a conductor of electricity.
A total of 165,000 tonnes of gold have been mined in human history, as of 2009. This is roughly equivalent to 5.3 billion troy ounces or, in terms of volume, about 8,500 mÂ³, or a cube 20.4 m on a side. The world consumption of new gold produced is about 50% in jewelry, 40% in investments, and 10% in industry.
Colombia is Latin America’s fifth largest producer of gold.
ORFG has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.
ORFG is a US (Nevada) company established for the purpose of creating a significant exploration and mining group operating in Colombia.
The major criteria for selection of properties will include:
- Significant historical production
- Favorable geology for hosting major ore bodies
- Significant property area for large target exploration
- Recent results available
- Favorable infrastructure and access to allow mine development
- Receptive local government and populace.
In addition ORFG has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the 1997-2000 time frame.
All properties meet the above criteria outlined above.
The second part of the Company’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. ORFG has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.
La Azul is one producing artesanal mine in the Senderos de Oro area controlled by ORFG, it is a mixed sequence of predominantly volcanic rocks with the vien systems comprised of high grade chalcopyrite, galena and sphalerite with pyrite in quartz viens.
It has been interpreted (by Shaw 1993) that the metallogenic zonation around the La Azul workings evokes a very viable “hidden porphyry” exploration model. This interpretation and the prospectivity of the area have been confirmed by the Orofino “qualified person” as per the 43-101 rules.
According to the company, ORFG will move ahead aggressively to persue the current interpretations, work programs and drilling will begin soon.
More about ORFG at www.orofinogold.com
Landec Corp. (Nasdaq:LNDC) reported results for the second quarter and first half of fiscal year 2011. For the second quarter of fiscal year 2011, revenues increased 15% to $70.2 million and net income increased 34% to $2.1 million compared to the second quarter of fiscal year 2010.
We increased revenues and net income during the second quarter of fiscal year 2011 compared to the second quarter of fiscal year 2010 due to our recently acquired hyaluronan-based biomaterials subsidiary, Lifecore Biomedical, Inc., which generated $8.4 million in revenues with a gross margin of 64% contributing $5.4 million in gross profit.
In our Apio, Inc. food business, as previously disclosed in our press release three weeks ago, prolonged cold and wet weather has adversely impacted produce sourcing for the produce industry and for Apio’s value-added, fresh-cut vegetable business, stated Gary Steele, Chairman and CEO of Landec.
Landec Corporation engages in the design, development, manufacture, and sale of temperature-activated and other specialty polymer products for various food products, agricultural products, and licensed partner applications in the United States.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.